肺炎鏈球菌疫苗市場規模、佔有率和成長分析：按疫苗類型、適應症、年齡層、產業、分銷管道和地區分類－2026-2033年產業預測

2024 年全球肺炎鏈球菌疫苗市場價值為 86.6 億美元，預計從 2025 年的 92 億美元成長到 2033 年的 148.8 億美元，預測期（2026-2033 年）複合年成長率為 6.2%。

全球肺炎鏈球菌疫苗市場正經歷顯著成長，主要驅動力是市場對結合疫苗和多醣體疫苗的需求不斷成長，以對抗肺炎鏈球菌引起的感染疾病。肺炎鏈球菌是一種可導致肺炎、腦膜炎和敗血症等嚴重的病原體。全球兒童免疫規劃的實施以及各國政府為中低收入國家舉措接種計畫提供資金的努力，尤其刺激了對價格合理的疫苗的需求。隨著各國衛生署為常規免疫接種撥款，製造商與當地企業之間的合作日益增多，從而提高了產能並增強了價格競爭力。此外，諸如全球疫苗免疫聯盟（Gavi）支持的疫苗計畫等成功案例表明，策略性資金如何能夠重振市場活力，拓展全球先進疫苗研發和分銷的機會，並最終改善健康狀況。

全球肺炎鏈球菌疫苗市場成長要素

隨著世界各國政府將肺炎鏈球菌疫苗納入嬰幼兒、老年人和高風險族群的國家免疫規劃，全球肺炎鏈球菌疫苗市場正經歷顯著成長。這項政策轉變在公共和私營部門都產生了持續的需求，促使生產商加強產能並投資建設完善的分銷體系。透過將肺炎鏈球菌疫苗納入常規醫療服務，衛生部門提高了更廣泛人群的疫苗接種覆蓋率，並增強了醫護人員和看護者的信心。這種穩定的採購模式不僅穩定了收入來源，還鼓勵持續的研發以改進疫苗，從而進一步推動市場擴張。

全球肺炎鏈球菌疫苗市場面臨的限制因素

肺炎鏈球菌疫苗的高成本給醫療衛生系統帶來了巨大的財政挑戰，尤其是在中低收入地區。當採購成本超過公共衛生預算時，衛生部門可能會選擇其他替代方案，甚至完全延遲疫苗接種。這些經濟限制會減少疫苗的供應量，並限制疫苗在疾病高發生地區的市場進入。因此，疫苗生產商的需求波動較大，難以實現規模經濟，並可能在不久的將來減緩新疫苗配方在全球各大洲的推廣應用。

全球肺炎鏈球菌疫苗市場趨勢

隨著醫療衛生系統日益認知到保護老年人和高風險成年人群的重要性，全球肺炎球菌疫苗市場正呈現出將成人免疫納入其中的顯著趨勢。這一轉變的促進因素包括人們對細菌性肺炎帶來的沉重負擔的認知不斷提高，以及人口老化帶來的人口結構變化。隨著各國免疫規劃擴大成人接種範圍，結合疫苗和多醣體疫苗的需求量激增。因此，生產商正致力於產品研發和策略行銷，旨在加強面向全球各領域養老機構和慢性病診所的分銷管道。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球肺炎鏈球菌疫苗市場規模：依疫苗類型分類

• 肺炎鏈球菌結合疫苗（PCV）
  • PCV13（普瑞納13）
  • PCV15（Vaxneuvance）
  • PCV20（前20）
  • PCV21（Capvaxive）
  • 其他
• 肺炎鏈球菌多醣體疫苗（PPSV）
  • PPSV23（23價肺炎鏈球菌疫苗）

全球肺炎鏈球菌疫苗市場規模：依適應症分類

• 侵襲性肺炎鏈球菌感染
• 肺炎
• 腦膜炎
• 中耳炎

全球肺炎鏈球菌疫苗市場規模：依年齡層別分類

• 兒童
• 成人
• 老年人

全球肺炎鏈球菌疫苗市場規模：依產業分類

• 公部門
• 私部門

全球肺炎鏈球菌疫苗市場規模：按分銷管道分類

• 政府機構
• 非政府組織/國際組織
• 經銷合作夥伴

全球肺炎鏈球菌疫苗市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Pfizer Inc.
• Merck & Co. Inc.
• GlaxoSmithKline PLC
• Sanofi SA
• Serum Institute of India Pvt. Ltd.
• Vaxcyte Inc.
• SK Bioscience Co. Ltd.
• Walvax Biotechnology Co. Ltd.
• Bharat Biotech International Ltd.
• Beijing Minhai Biological Technology Co. Ltd.
• AIM Vaccine Co. Ltd.
• Panacea Biotec Ltd.
• LG Chem Ltd.
• Takeda Pharmaceutical Company Ltd.
• Biological E Ltd.
• KM Biologics Co. Ltd.
• CSL Behring
• AstraZeneca PLC
• Institut Pasteur de Dakar

結論與建議

Global Pneumococcal Vaccines Market size was valued at USD 8.66 Billion in 2024 and is poised to grow from USD 9.2 Billion in 2025 to USD 14.88 Billion by 2033, growing at a CAGR of 6.2% during the forecast period (2026-2033).

The global pneumococcal vaccines market is experiencing significant growth driven by the increasing demand for conjugate and polysaccharide immunizations to combat infections caused by Streptococcus pneumoniae, a pathogen responsible for severe illnesses such as pneumonia, meningitis, and sepsis. This market is particularly influenced by the global adoption of pediatric immunization programs and governmental efforts to fund vaccination initiatives in low- and middle-income countries, fostering demand for affordable vaccine options. Partnerships between manufacturers and regional companies are emerging as national health ministries allocate funds for routine immunization, leading to enhanced production capabilities and competitive pricing. Additionally, successful initiatives, such as the Gavi-supported rollout of vaccine programs, illustrate how strategic financing can stimulate market activity and expand opportunities for advanced vaccine development, distribution, and improved health outcomes worldwide.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pneumococcal Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pneumococcal Vaccines Market Segments Analysis

Global pneumococcal vaccines market is segmented by vaccine type, indication, age group, sector, distribution channel and region. Based on vaccine type, the market is segmented into pneumococcal conjugate vaccines (PCV) and pneumococcal polysaccharide vaccines (PPSV). Based on indication, the market is segmented into invasive pneumococcal disease, pneumonia, meningitis and otitis media. Based on age group, the market is segmented into pediatric, adult and geriatric. Based on sector, the market is segmented into public sector and private sector. Based on distribution channel, the market is segmented into government authorities, NGOs / international agencies and distribution partners. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pneumococcal Vaccines Market

The global market for pneumococcal vaccines is experiencing substantial growth as governments around the world incorporate these vaccines into national immunization programs, targeting infants, the elderly, and high-risk groups. This policy shift is generating sustained demand across both public and private sectors, prompting manufacturers to enhance production capabilities and invest in robust distribution systems. By integrating pneumococcal vaccines into routine health services, health authorities facilitate broader population coverage, fostering increased confidence among healthcare professionals and caregivers. This reliable purchasing pattern not only stabilizes revenue streams but also propels continuous research and development in vaccine enhancements, further driving market expansion.

Restraints in the Global Pneumococcal Vaccines Market

The high costs associated with pneumococcal vaccines pose significant financial challenges for healthcare systems, especially in low- and middle-income regions. When procurement expenses surpass public health budgets, health authorities might opt for alternative measures or postpone the introduction of vaccines altogether. Such economic constraints diminish the number of doses that can be acquired, restricting market access in regions where disease prevalence is most severe. Consequently, this leads to inconsistent demand for manufacturers, hindering their ability to achieve economies of scale and potentially delaying the global dissemination of newer vaccine formulations across various continents in the foreseeable future.

Market Trends of the Global Pneumococcal Vaccines Market

The Global Pneumococcal Vaccines market is witnessing a significant trend towards the inclusion of adult immunization, as healthcare systems increasingly recognize the importance of protecting elderly and high-risk adult populations. This shift is spurred by a heightened awareness of the substantial burden posed by bacterial pneumonia, coupled with demographic changes reflecting an ageing population. As national immunization programs broaden their guidelines to encompass adult dosing, the demand for both conjugate and polysaccharide vaccine formulations is surging. Consequently, manufacturers are intensifying their focus on product development and strategic marketing, aiming to enhance distribution channels targeting senior care facilities and chronic-illness clinics across various sectors globally.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Pneumococcal Vaccines Market Size by Vaccine Type & CAGR (2026-2033)

• Market Overview
• Pneumococcal Conjugate Vaccines (PCV)
  • PCV13 (Prevnar 13)
  • PCV15 (Vaxneuvance)
  • PCV20 (Prevnar 20)
  • PCV21 (Capvaxive)
  • Others
• Pneumococcal Polysaccharide Vaccines (PPSV)
  • PPSV23 (Pneumovax 23)

Global Pneumococcal Vaccines Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Invasive Pneumococcal Disease
• Pneumonia
• Meningitis
• Otitis Media

Global Pneumococcal Vaccines Market Size by Age Group & CAGR (2026-2033)

• Market Overview
• Pediatric
• Adult
• Geriatric

Global Pneumococcal Vaccines Market Size by Sector & CAGR (2026-2033)

• Market Overview
• Public Sector
• Private Sector

Global Pneumococcal Vaccines Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Government Authorities
• NGOs / International Agencies
• Distribution Partners

Global Pneumococcal Vaccines Market Size & CAGR (2026-2033)

• North America (Vaccine Type, Indication, Age Group, Sector, Distribution Channel)
  • US
  • Canada
• Europe (Vaccine Type, Indication, Age Group, Sector, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Vaccine Type, Indication, Age Group, Sector, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Vaccine Type, Indication, Age Group, Sector, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Vaccine Type, Indication, Age Group, Sector, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Serum Institute of India Pvt. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vaxcyte Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SK Bioscience Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Walvax Biotechnology Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bharat Biotech International Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beijing Minhai Biological Technology Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AIM Vaccine Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Panacea Biotec Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LG Chem Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biological E Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KM Biologics Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Behring
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Institut Pasteur de Dakar
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations